Serevent nationwide surveillance study: comparison ofsalmeterol with salbutamol in asthmatic patients

serum of three tumour-associated antigens: CA 125, placental alkaline phosphatase and HMFG2 in ovarian carcinoma. Br J Obstet Gynaecol 1987;94:696-8. 16 Schwartz PE, Chambers SK, Chambers JT, Gutmann J, Katopodis N, Foemmel R. Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer 1987;60:353-61. 17 Cole LA, Nam J-H, Chambers JT, Schwartz PE. Urinary gonadotrophin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass. Gynecol Oncol 1990;36:391-4. 18 Kacinski BM, Chambers SK, Carter D, Filderman AE, Stanley ER. The macrophage colony stimulating factor CSF1, an autoand paracrine tumour cytokine is also a circulating 'tumor marker' in patients with ovarian, endometrial and pulmonary neoplasms. In: Dinarello CA, Kluger MJ, Powanda MC, Oppenheim JJ, eds. The physiological and pathological effects ofcytokines. New York: Wiley-Liss, 1990:393-400. 19 Jacobs IJ, Oram DH, Bast RC Jr. Strategies for improving the specificity of screening for ovarian cancer with tumor associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 1992;80:396-9. 20 Zurawski VR, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC Jr, et al. Prospective evaluation of serum CA 125 levels in a normal population, Phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 1990;36:299-305. 21 Narod SA, Feunteun J, Lynch HT. Familial breast-ovarian cancer locus on chromosome 17ql2-q23. Lancet 1991;338:82-3.